321195-88-4

Basic information

• Product Name: 3-(TRIFLUOROMETHOXY)BENZHYDRAZIDE
• Synonyms: 3-(TRIFLUOROMETHOXY)BENZHYDRAZIDE;3-(TRIFLUOROMETHOXY)BENZOIC ACID HYDRAZIDE;3-(trifluoroMethoxy)benzohydrazide
• CAS NO: 321195-88-4
• Molecular Formula: C₈H₇F₃N₂O₂
• Molecular Weight: 220.15
• Mol File: 321195-88-4.mol

Chemical Properties

• Melting Point: 94-96°C
• Appearance: /
• Density: 1.399g/cm³
• Refractive Index: 1.495
• Storage Temp.: Store Cold
• PKA: 11.74±0.10(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 3-(TRIFLUOROMETHOXY)BENZHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(TRIFLUOROMETHOXY)BENZHYDRAZIDE(321195-88-4)
• EPA Substance Registry System: 3-(TRIFLUOROMETHOXY)BENZHYDRAZIDE(321195-88-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 321195-88-4(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
3-(TRIFLUOROMETHOXY)BENZHYDRAZIDE is used as a chemical intermediate for the synthesis of various organic compounds. Its unique functional groups and reactivity make it a valuable component in the development of new chemical entities.
Used in Research:
3-(TRIFLUOROMETHOXY)BENZHYDRAZIDE is employed as a research compound to study its chemical properties, reactivity, and potential applications in different fields. It aids scientists in understanding its behavior and exploring its use in creating new materials or pharmaceuticals.
Used in Pharmaceutical Development:
Although its specific applications are still under investigation, 3-(TRIFLUOROMETHOXY)BENZHYDRAZIDE may be used as a precursor in the development of pharmaceuticals. Its unique structure and functional groups could potentially contribute to the creation of new drugs with novel therapeutic properties.
Used in Material Science:
3-(TRIFLUOROMETHOXY)BENZHYDRAZIDE could be utilized in the field of material science for the development of new materials with specific properties. Its reactivity and stability may contribute to the creation of advanced materials with applications in various industries.

InChI:InChI=1/C8H7F3N2O2/c9-8(10,11)15-6-3-1-2-5(4-6)7(14)13-12/h1-4H,12H2,(H,13,14)

Upstream product

• 1014-81-9 3-(trifluoromethoxy)benzoic acid 
• 148438-00-0 3-trifluoromethoxybenzoic acid methyl ester 
• 677713-01-8 ethyl 3-(trifluoromethoxy)benzoate 

Downstream Products

• 1018838-63-5 3-(3-nitro-phenyl)-5-(3-trifluoromethoxy-phenyl)-4H-[1,2,4]-triazole 
• 1235563-15-1 3-trifluoromethoxybenzoic acid [1-(3,5-dichloro-2-hydroxyphenyl)methylidene]hydrazide 
• 1313733-16-2 5-piperidin-1-yl-3-(3-trifluoromethoxy-phenyl)-7,8-dihydro-6,9-dioxa-1,2,3a,4-tetraazacyclopenta[a]naphthalene 
• 1313733-17-3 cyclopropylmethyl-[3-(3-trifluoromethoxy-phenyl)-7,8-dihydro-6,9-dioxa-1,2,3a,4-tetraaza-cyclopenta[a]naphthalen-5-yl]-amine 
• 1313733-32-2 5-chloro-9-methyl-3-(3-trifluoromethoxy-phenyl)-8,9-dihydro-7H-6-oxa-1,2,3a,4,9-pentaaza-cyclopenta[a]naphthalene 
• 1313733-33-3 5-chloro-6-methyl-3-(3-trifluoromethoxy-phenyl)-7,8-dihydro-6H-9-oxa-1,2,3a,4,6-pentaaza-cyclopenta[a]naphthalene 
• 1417848-73-7 C₁₅H₁₀ClF₃N₄O₂ 
• 1417848-82-8 C₁₅H₁₀ClF₃N₄O₂ 
• 1417848-92-0 C₁₅H₁₀ClF₃N₄O₂ 
• 1417840-38-0 C₂₂H₂₅F₃N₆O₂*CH₂O₂ 
• 1417847-24-5 C₁₆H₁₁ClF₅N₅O₂ 
• 1417847-35-8 C₁₆H₁₁ClF₅N₅O₂ 
• 1417848-68-0 C₁₅H₁₀ClF₃N₄O₂ 
• 1417848-71-5 C₁₅H₁₂ClF₃N₄O₃ 

Relevant articles and documents

SAR Studies on Aromatic Acylhydrazone-Based Inhibitors of Fungal Sphingolipid Synthesis as Next-Generation Antifungal Agents

Recently, the fungal sphingolipid glucosylceramide (GlcCer) synthesis has emerged as a highly promising new target for drug discovery of next-generation antifungal agents, and we found two aromatic acylhydrazones as effective inhibitors of GlcCer synthesis based on HTP screening. In the present work, we have designed libraries of new aromatic acylhydrazones, evaluated their antifungal activities (MIC80 and time-kill profile) against C. neoformans, and performed an extensive SAR study, which led to the identification of five promising lead compounds, exhibiting excellent fungicidal activities with very large selectivity index. Moreover, two compounds demonstrated broad spectrum antifungal activity against six other clinically relevant fungal strains. These five lead compounds were examined for their synergism/cooperativity with five clinical drugs against seven fungal strains, and very encouraging results were obtained; e.g., the combination of all five lead compounds with voriconazole exhibited either synergistic or additive effect to all seven fungal strains.

SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS

Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided, are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS

There is provided compounds of formula (I), wherein R1, R2, X, R3 and R4 have meanings given in the description (and which compounds are optionally substituted as indicated in the description), and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PIM-2 and/or PIM-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. There is also provided combinations comprising the compounds of formula (I).

Triazole derivatives

The present invention relates to triazole and imidazole derivatives of formula I and to their pharmaceutically acceptable acid addition salts. These compounds are NMDA receptor subtype blockers and are useful for the treatment of diseases related to the NMDA receptor.